NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Conducting Clinical Trial Using Electroceuticals for Traumatic Brain Injury

May 23, 2019 13:20:17

Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, was recently featured in an article on BoldBusiness.comtitled ‘Non-Invasive Electroceuticals Accelerate Healing In Traumatic Brain Injury Patients’. The article shines a light on ENDV’s study to find the impact of non-invasive electroceuticals to manage traumatic brain injury (“TBI”). ENDV enrolled the first TBI patient for study in June 2018 and aims to enroll a total of 48 participants with TBI. The study will measure inflammatory chemicals as well as neurological outcomes between participants receiving electroceuticals treatment and controls. Furthermore, Endonovo is also pursuing research and product development in several other areas of healthcare. “We believe our technology, whose proven mechanism of action is the suppression of inflammation, has the potential to change the treatment of central nervous system disorders where neuroinflammation propagates injury such as ischemic stroke, Alzheimer’s disease and multiple sclerosis,” Endonovo Therapeutics CEO Alan Collier stated in the article.

To view the full article, visit

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals (TM) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(TM) therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, post- concussion syndrome and multiple sclerosis. The company’s non-invasive Electroceutical(TM) therapeutic device, SofPulse(R), using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The company’s current portfolio of pre-clinical stage Electroceuticals(TM) therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The company’s non-invasive, wearable Electroceuticals(TM) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. For more information, visit the company’s website at

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office